Advertisement

Organs at risk in lung SBRT

Published:April 19, 2017DOI:https://doi.org/10.1016/j.ejmp.2017.04.010

      Highlights

      • SBRT is a valid option for early stage and oligometastatic lung diseases.
      • A non-systematic review of dose constraints for main organs at risk is performed.
      • OAR delineation, toxicities and dosimetric parameters are analyzed for each organ.
      • Data reported are the best possible data obtainable from the present literature.
      • Ongoing prospective trials should provide further evidence on SBRT safety.

      Abstract

      Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high ‘ablative’ doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications. In this heterogeneous scenario, a non-systematic review of dose constraints for lung SBRT was performed, including the main organs at risk in the thorax.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Physica Medica: European Journal of Medical Physics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fogliata A.
        • Cozzi L.
        Dose calculation algorithm accuracy for small fields in non-homogeneous media: the lung SBRT case.
        Phys Med. 2017; 44: 157-162https://doi.org/10.1016/j.ejmp.2016.11.104
        • Zheng D.
        • Zhu X.
        • Zhang Q.
        • Liang X.
        • Zen W.
        • Lin C.
        • et al.
        Target dose conversion modeling from pencil beam (PB) to Monte Carlo (MC) for lung SBRT.
        Radiat Oncol. 2016; 11: 83
        • Schuring D.
        • Hurkmans C.W.
        Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose.
        Radiat Oncol. 2008; 3: 21
        • Kang Kylie H.
        • Okoye Christian C.
        • Patel Ravi B.
        • Siva Shankar
        • Biswas Tithi
        • Ellis Rodney J.
        • et al.
        Complications from stereotactic body radiotherapy for lung cancer.
        Cancers. 2015; 7: 981-1004
        • Marks L.B.
        • Bentzen S.M.
        • Deasy J.O.
        • Kong F.M.
        • Bradley J.D.
        • Vogelius I.S.
        • et al.
        Radiation dose-volume effects in the lung.
        Int J Radiat Oncol Biol Phys. 2010; 76 (Supplement): S70-S76
        • Timmerman R.
        • McGarry R.
        • Yiannoutsos C.
        • Papiez L.
        • Tudor K.
        • DeLuca J.
        • et al.
        Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
        J Clin Oncol. 2006; 24: 4833-4839
        • Yamashita H.
        • Nakagawa K.
        • Nakamura N.
        • Koyanagi H.
        • Tago M.
        • Igaki H.
        • et al.
        Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.
        Radiat Oncol. 2007; 7: 21
        • Barriger R.B.
        • Forquer J.A.
        • Brabham J.G.
        • Andolino D.L.
        • Shapiro R.H.
        • Henderson M.A.
        • et al.
        A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
        Int J Radiat Oncol Biol Phys. 2012; 82: 457-462
        • Baker R.
        • Han G.
        • Sarangkasiri S.
        • DeMarco M.L.
        • Turke C.
        • Stevens C.W.
        • et al.
        Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
        Int J Radiat Oncol Biol Phys. 2013; 85: 190-195
        • Chang J.Y.
        • Liu H.
        • Balter P.
        • Komaki R.
        • Liao Z.
        • Welsh J.
        • et al.
        Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
        Radiat Oncol. 2012; 7: 152
        • Takeda A.
        • Tohashi T.
        • Kunieda E.
        • Sanuki N.
        • Enomoto T.
        • Takeda T.
        • et al.
        Comparison of clinical, tumour-related and dosimetric factors in grade 0–1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
        Br J Radiol. 2012; 85: 636-642
        • Borst G.R.
        • Ishikawa M.
        • Nijkamp J.
        • Hauptmann M.
        • Shirato H.
        • Onimaru R.
        • et al.
        Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy.
        Radiother Oncol. 2009; 91: 307-313
        • Bongers E.M.
        • Botticella A.
        • Palma D.A.
        • Haasbeek C.J.A.
        • Warner A.
        • Verbakel W.
        • et al.
        Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.
        Radiother Oncol. 2013; 109: 95-99
        • Chang J.Y.
        • Li Q.Q.
        • Xu Q.Y.
        • Allen P.K.
        • Rebueno N.
        • Gomez D.R.
        • et al.
        Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “No Fly Zone”.
        Int J Radiat Oncol Biol Phys. 2014 Apr 1; 88: 1120-1128
        • Gagliardi G.
        • Constine L.S.
        • Moiseenko V.
        • Correa C.
        • Pierce L.J.
        • Allen A.M.
        • et al.
        Radiation dose-volume effects in the heart.
        Int J Radiat Oncol Biol Phys. 2010; 76 (Supplement): S77-S85
        • Bonomo P.
        • Livi L.
        • Rampini A.
        • Meattini I.
        • Agresti B.
        • Simontacchi G.
        • et al.
        Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience.
        Radiol Med. 2013; 118: 1055-1065
        • Evans J.D.
        • Gomez D.R.
        • Chang J.Y.
        • Gladish G.W.
        • Erasmus J.J.
        • Rebueno N.
        • et al.
        Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy.
        Radiother Oncol. 2013; 109: 82-88
        • Fakiris A.J.
        • McGarry R.C.
        • Yiannoutsos C.T.
        • Papiez L.
        • Williams M.
        • Henderson M.A.
        • et al.
        Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase ii study.
        Int J Radiat Oncol Biol Phys. 2009; 75: 677-682
        • Song S.Y.
        • Choi W.
        • Shin S.S.
        • Lee S.W.
        • Ahn S.D.
        • Kim J.H.
        • et al.
        Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.
        Lung Cancer. 2009; 66: 89-93
        • Karlsson K.
        • Nyman J.
        • Baumann P.
        • Wersall P.
        • Drugge N.
        • Gagliardi G.
        • et al.
        Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree.
        Int J Radiat Oncol Biol Phys. 2013; 87: 590-595
        • Kelsey C.R.
        • Kahn D.
        • Hollis D.R.
        • et al.
        Radiation-induced narrowing of the tracheobronchial tree: an in-depth analysis.
        Lung Cancer. 2006; 52: 111-116
        • Duijm M.
        • Schillemans W.
        • Aerts J.G.
        • et al.
        Dose and volume of the irradiated main bronchi and related side effects in the treatment of central lung tumors with stereotactic radiotherapy.
        Semin Radiat Oncol. 2016; 26: 140-148
        • Kong F.M.
        • Ritter T.
        • Quint D.J.
        • et al.
        Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.
        Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81: 1442-1457
        • Timmerman R.
        • Papiez L.
        • McGarry R.
        • Likes L.
        • DesRosiers C.
        • Frost S.
        • et al.
        Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.
        Chest. 2003; 124: 1946-1955
        • Onimaru R.
        • Shirato H.
        • Shimizu S.
        • Kitamura K.
        • Xu B.
        • Fukumoto S.
        • et al.
        Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
        Int J Radiat Oncol Biol Phys. 2003; 56: 126-135
        • Cox B.W.
        • Jackson A.
        • Hunt M.
        • et al.
        Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery.
        Int J Radiation Oncol Biol Phys. 2012; 83: e661-e667
        • Abelson J.A.
        • Murphy J.D.
        • Loo Jr, B.W.
        • et al.
        Esophageal tolerance to high dose stereotactic ablative radiotherapy.
        Dis Esophagus. 2012; 25: 623-629
        • Nuyttens J.J.
        • Moiseenko V.
        • McLaughlin M.
        • et al.
        Esophageal dose tolerance in patients treated with stereotactic body radiation therapy.
        Semin Radiat Oncol. 2016; 26: 120-128
        • Evans J.
        • Gomez D.
        • Amini A.
        • Rebueno N.
        • Allen P.
        • Martel M.
        • et al.
        Aortic dose constraints when reirradiating thoracic tumors.
        Radiother Oncol. 2013; 106: 327-332
        • Ito M.
        • Niho S.
        • Nihei K.
        • Yoh K.
        • Ohmatsu H.
        • Ohe Y.
        Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy.
        BMC Cancer. 2012; 12
        • Reck M.
        • Barlesi F.
        • Crino L.
        • Henschke C.I.
        • Isla D.
        • Stiebeler S.
        • et al.
        Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
        Ann Oncol. 2012; 23: 1111-1120
        • Xue J.
        • Kubicek G.
        • Patel A.
        • et al.
        Validity of current stereotactic body radiation therapy dose constraints for aorta and major vessels.
        Semin Radiat Oncol. 2016; 26: 135-139
        • Grimm J.
        • Sahgal A.
        • Soltys S.G.
        • Luxton G.
        • Patel A.
        • Herbert S.
        • et al.
        Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord.
        Semin Radiat Oncol. 2016 Apr; 26: 165-171
        • Sahgal A.
        • Larson D.A.
        • Chang E.L.
        Stereotactic body radiosurgery for spinal metastases: a critical review.
        Int J Radiat Oncol Biol Phys. 2008; 71: 652-665
        • Chang E.L.
        • Shiu A.S.
        • Mendel E.
        • Mathews L.A.
        • Mahajan A.
        • Allen P.K.
        • et al.
        Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure.
        J Neurosurg Spine. 2007; 7: 151-160
        • Sahgal A.
        • Chou D.
        • Ames C.
        • Ma L.
        • Lamborn K.
        • Huang K.
        • et al.
        Image-guided robotic stereotactic body radiotherapy for benign spinal tumors: the University of California San Francisco preliminary experience.
        Technol Cancer Res Treat. 2007; 6: 595-604
        • Kirkpatrick J.P.
        • van der Kogel A.J.
        • Schultheiss T.E.
        Radiation dose-volume effects in the spinal cord.
        Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76: S42-S49
        • Wong C.S.
        • Van Dyk J.
        • Milosevic M.
        • Laperriere N.J.
        Radiation myelopathy following single courses of radiotherapy and retreatment.
        Int J Radiat Oncol Biol Phys. 1994; 30: 575-581
        • Sahgal A.
        • Ma L.
        • Gibbs I.
        • Gerszten P.C.
        • Ryu S.
        • Soltys S.
        • et al.
        Spinal cord tolerance for stereotactic body radiotherapy.
        Int J Radiat Oncol Biol Phys. 2010; 77: 548-553
        • Chang B.K.
        • Timmerman R.D.
        Stereotactic body radiation therapy: a comprehensive review.
        J Clin Oncol. 2007; 30: 637-644
        • Dodd R.L.
        • Ryu M.R.
        • Kamnerdsupaphon P.
        • Gibbs I.C.
        • Chang Jr, S.D.
        • Adler Jr, J.R.
        CyberKnife radiosurgery for benign intradural extramedullary spinal tumors.
        Neurosurgery. 2006 Apr; 58: 674-685
        • Timmerman R.D.
        An overview of hypofractionation and introduction to this issue of seminars in radiation oncology.
        Semin Radiat Oncol. 2008; 18: 215-222
      1. Bezhak A, Bradley J, Gaspar L, Timmerman R, Papiez L, Gore E, Kong F, Bae K, Normolle, D. Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. Radiation Therapy Oncology Group 0813. Accessed at http://www.rtog.org.

        • Kong F.M.
        • Ritter T.
        • Quint D.J.
        • Senan S.
        • Gaspar L.E.
        • Komaki R.U.
        • et al.
        Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.
        Int J Radiat Oncol Biol Phys. 2011 December 1; 81: 1442-1457
        • Hall W.H.
        • Guiou M.
        • Lee N.Y.
        • Dublin A.
        • Narayan S.
        • Vijayakumar S.
        • et al.
        Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72: 1362-1367
        • Schierle C.
        • Winograd J.M.
        Radiation-induced brachial plexopathy: review. complication without a cure.
        J Reconstr Microsurg. 2004; 20: 149-152
        • Amini A.
        • Yang J.
        • Williamson R.
        • McBurney M.L.
        • Erasmus Jr, J.
        • Allen P.K.
        • et al.
        Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer.
        Int J Radiat Oncol Biol Phys. 2012; 82: e391-e398
        • Ferrante M.A.
        Brachial plexopathies: classification, causes, and consequences.
        Muscle Nerve. 2004; 30: 547-568
        • Forquer J.A.
        • Fakiris A.J.
        • Timmerman R.D.
        • Lo S.S.
        • Perkins S.M.
        • McGarry R.C.
        • et al.
        Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.
        Radiother Oncol. 2009; 93: 408-413
        • Dunlap N.E.
        • Cai J.
        • Biedermann G.B.
        • Yang W.
        • Benedict S.H.
        • Sheng K.
        • et al.
        Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
        Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76: 796-801
        • Pettersson N.
        • Nyman J.
        • Johansson K.A.
        Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis.
        Radiother Oncol. 2009 Jun; 91: 360-368
        • Stephans K.L.
        • Djemil T.
        • Tendulkar R.D.
        • Robinson C.G.
        • Reddy C.A.
        • Videtic G.M.
        Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT).
        Int J Radiat Oncol Biol Phys. 2012 Feb 1; 82: 974-980
        • Mutter R.W.
        • Liu F.
        • Abreu A.
        • Yorke E.
        • Jackson A.
        • Rosenzweig K.E.
        Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.
        Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82: 1783-1790
        • Welsh J.
        • Thomas J.
        • Shah D.
        • Allen P.K.
        • Wei X.
        • Mitchell K.
        • et al.
        Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy.
        Int J Radiat Oncol Biol Phys. 2011 Sep 1; 81: 91-96
        • Andolino D.L.
        • Forquer J.A.
        • Henderson M.A.
        • Barriger R.B.
        • Shapiro R.H.
        • Brabham J.G.
        • et al.
        Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver.
        Int J Radiat Oncol Biol Phys. 2011; 80: 692-697
        • Li Q.
        • Swanick C.W.
        • Allen P.K.
        • Gomez D.R.
        • Welsh J.W.
        • Liao Z.
        • et al.
        Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
        Radiother Oncol. 2014 Aug; 112: 256-261
        • Hoppe B.S.
        • Laser B.
        • Kowalski A.V.
        • Fontenla S.C.
        • Pena-Greenberg E.
        • Yorke E.D.
        • et al.
        Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: Who’s at risk?.
        Int J Radiat Oncol Biol Phys. 2008; 72: 1283-1286
        • Adebahr S.
        • Collette S.
        • Shash E.
        • Lambrecht M.
        • Le Pechoux C.
        • Faivre-Finn C.
        • et al.
        LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.
        Br J Radiol. 2015 Jul; 88: 20150036
        • Chang J.Y.
        • Bezjak A.
        • Mornex F.
        IASLC advanced radiation technology committee. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer. What we have learned.
        J Thorac Oncol. 2015 Apr; 10: 577-585
        • Larson D.
        • Ma L.
        • Ames C.
        • et al.
        Safe spinal cord and cauda equina partial volume tolerances for spinous/paraspinous radiosurgery.
        Int J Radiat Oncol Biol Phys. 2007; 69: S164-S165